News

Researchers Identify Molecular Pathway Leading to Neuronal Loss, Heart Disease in Mice with Friedreich’s Ataxia

Researchers have identified the molecular mechanism through which loss of frataxin, the protein missing in Friedreich’s ataxia (FA), causes cell damage leading to neurodegeneration, according to a new mouse study. This finding may prove helpful in designing new therapies to treat Friedreich’s ataxia patients. The study, “Loss Of Frataxin…

Analyzing Speech Disparities in Friedreich’s Ataxia Could Help Manage the Condition

Analyzing speech disparity in Friedreich’s ataxia using a program called Analysis of Dysphonia in Speech and Voice (ADSV) provides a measure that has excellent sensitivity and specificity, according to a study published in the Journal of Voice. Finding a good measure that can track disease progression and determine the effectiveness of any treatment is vital for the management of Friedreich’s ataxia. According to the authors, a better understanding of the condition can help optimize the communication abilities, occupational success, and social interactions of the affected people.

Patients with Late-onset Friedrich’s Ataxia May Have Different States of Sensory Nerve Conduction

Patients with late-onset Friedrich’s ataxia (LOFA) may present variable sensory nerve conduction, according to new research. The study, “Variable Sensory Nerve Conduction Parameters In Late Onset Friedreich Ataxia,” was published in the journal Muscle & Nerve. Nerve conduction studies are commonly performed by neurology specialists to assess the…

‘Genome Guardian’ May Prevent Development of Friedreich’s Ataxia, Other Neurological Disorders

The loss of function of proteins associated with RNA, the transition molecule between DNA and protein, could contribute to neurological disorders such as Friedreich’s ataxia. In a recent review titled “Senataxin: Genome Guardian at the Interface of Transcription and Neurodegeneration” and published in the Journal of Molecular Biology, a team of researchers from the University of Oxford in the U.K. led by Dr. Natalia Gromak focus on one such protein called senataxin (SETX) and the role it plays as a “genome guardian” preventing the development of neurological diseases.